NCT04209829View on ClinicalTrials.gov

Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics

Not yet recruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

December 31, 2019

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2035

Conditions
Hematologic Diseases
All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04209829 - Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics | Biotech Hunter | Biotech Hunter